MRPL15 and ovarian carcinoma: As shown in Table 5, the high positive rate of MRPL15 expression in patients with epithelial ovarian cancer at FIGO stage III/IV (93.02%) was significantly higher than in patients at FIGO stage I/II (76.32%; p = 0.035).